Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C.

Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Forsman Quigley A, Hulsik DL, Chen L, Weiss R, de Haard H, Verrips T.

PLoS One. 2012;7(3):e33298. doi: 10.1371/journal.pone.0033298. Epub 2012 Mar 15.

2.

Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Diskin R, Scheid JF, Marcovecchio PM, West AP Jr, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ.

Science. 2011 Dec 2;334(6060):1289-93. doi: 10.1126/science.1213782. Epub 2011 Oct 27.

3.

Nanobodies®: new ammunition to battle viruses.

Vanlandschoot P, Stortelers C, Beirnaert E, Ibañez LI, Schepens B, Depla E, Saelens X.

Antiviral Res. 2011 Dec;92(3):389-407. doi: 10.1016/j.antiviral.2011.09.002. Epub 2011 Sep 10. Review.

PMID:
21939690
4.

Llama antibody fragments have good potential for application as HIV type 1 topical microbicides.

Gorlani A, Brouwers J, McConville C, van der Bijl P, Malcolm K, Augustijns P, Quigley AF, Weiss R, De Haard H, Verrips T.

AIDS Res Hum Retroviruses. 2012 Feb;28(2):198-205. doi: 10.1089/aid.2011.0133. Epub 2011 Aug 24.

PMID:
21864083
5.

Broad neutralization coverage of HIV by multiple highly potent antibodies.

Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD; Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P.

Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.

6.

Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.

Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC.

Science. 2011 Sep 16;333(6049):1633-7. doi: 10.1126/science.1207227. Epub 2011 Jul 14.

7.

Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.

Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR.

J Virol. 2011 Sep;85(17):8954-67. doi: 10.1128/JVI.00754-11. Epub 2011 Jun 29.

8.

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP.

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11181-6. doi: 10.1073/pnas.1103012108. Epub 2011 Jun 20.

9.

LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays.

Piehler B, Nelson EK, Eckels J, Ramsay S, Lum K, Wood B, Greene KM, Gao H, Seaman MS, Montefiori DC, Igra M.

BMC Immunol. 2011 May 27;12:33. doi: 10.1186/1471-2172-12-33.

10.

Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.

Brinckmann S, da Costa K, van Gils MJ, Hallengärd D, Klein K, Madeira L, Mainetti L, Palma P, Raue K, Reinhart D, Reudelsterz M, Ruffin N, Seifried J, Schäfer K, Sheik-Khalil E, Sköld A, Uchtenhagen H, Vabret N, Ziglio S, Scarlatti G, Shattock R, Wahren B, Gotch F.

J Transl Med. 2011 Apr 12;9:40. doi: 10.1186/1479-5876-9-40.

11.

An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV.

Watkins JD, Siddappa NB, Lakhashe SK, Humbert M, Sholukh A, Hemashettar G, Wong YL, Yoon JK, Wang W, Novembre FJ, Villinger F, Ibegbu C, Patel K, Corti D, Agatic G, Vanzetta F, Bianchi S, Heeney JL, Sallusto F, Lanzavecchia A, Ruprecht RM.

PLoS One. 2011 Mar 31;6(3):e18207. doi: 10.1371/journal.pone.0018207.

12.

Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.

Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, Goepfert P, McElrath MJ, Lu S.

PLoS One. 2010 Nov 9;5(11):e13916. doi: 10.1371/journal.pone.0013916.

13.

Induction of immunity to human immunodeficiency virus type-1 by vaccination.

McElrath MJ, Haynes BF.

Immunity. 2010 Oct 29;33(4):542-54. doi: 10.1016/j.immuni.2010.09.011. Review.

14.

AIDS/HIV. A boost for HIV vaccine design.

Burton DR, Weiss RA.

Science. 2010 Aug 13;329(5993):770-3. doi: 10.1126/science.1194693. No abstract available.

PMID:
20705840
15.

Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.

Sundling C, Forsell MN, O'Dell S, Feng Y, Chakrabarti B, Rao SS, Loré K, Mascola JR, Wyatt RT, Douagi I, Karlsson Hedestam GB.

J Exp Med. 2010 Aug 30;207(9):2003-17. doi: 10.1084/jem.20100025. Epub 2010 Aug 2. Erratum in: J Exp Med. 2010 Sep 27;207(10):2283.

16.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.

17.

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR.

Science. 2010 Aug 13;329(5993):856-61. doi: 10.1126/science.1187659. Epub 2010 Jul 8.

18.

Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.

Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD.

Science. 2010 Aug 13;329(5993):811-7. doi: 10.1126/science.1192819. Epub 2010 Jul 8.

19.

Crystal structure of the neutralizing Llama V(HH) D7 and its mode of HIV-1 gp120 interaction.

Hinz A, Lutje Hulsik D, Forsman A, Koh WW, Belrhali H, Gorlani A, de Haard H, Weiss RA, Verrips T, Weissenhorn W.

PLoS One. 2010 May 5;5(5):e10482. doi: 10.1371/journal.pone.0010482.

20.

Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1.

Koh WW, Steffensen S, Gonzalez-Pajuelo M, Hoorelbeke B, Gorlani A, Szynol A, Forsman A, Aasa-Chapman MM, de Haard H, Verrips T, Weiss RA.

J Biol Chem. 2010 Jun 18;285(25):19116-24. doi: 10.1074/jbc.M110.116699. Epub 2010 Apr 16.

Supplemental Content

Support Center